These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 3943469

  • 21. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I, Hatzidimitriou-Papazacharia K, Spiliotopoulou J, Tsagarakis N, Digenopoulou E.
    Birth Defects Orig Artic Ser; 1988; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract] [Full Text] [Related]

  • 22. Rubber band technique for slow subcutaneous infusion of desferrioxamine (Desferal).
    Hathirat P, Isarangkura P, Panthangkura W, Chuansumrit A, Sasanakul W, Kanasit R.
    Birth Defects Orig Artic Ser; 1988; 23(5B):123-7. PubMed ID: 3390534
    [Abstract] [Full Text] [Related]

  • 23. Iron chelating therapy in thalassemia: current problems.
    Russo G.
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract] [Full Text] [Related]

  • 24. Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens.
    Viprakasit V, Tanphaichitr VS, Mahasandana C, Assteerawatt A, Suwantol L, Veerakul G, Kankirawatana S, Pung-Amritt P, Suvatte V.
    J Med Assoc Thai; 2001 Jul; 84(7):929-41. PubMed ID: 11759973
    [Abstract] [Full Text] [Related]

  • 25. The changing profile of homozygous beta-thalassemia: demography, ethnicity, and age distribution of current North American patients and changes in two decades.
    Pearson HA, Cohen AR, Giardina PJ, Kazazian HH.
    Pediatrics; 1996 Mar; 97(3):352-6. PubMed ID: 8604269
    [Abstract] [Full Text] [Related]

  • 26. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
    Orton RB, de Veber LL, Sulh HM.
    Can J Ophthalmol; 1985 Jun; 20(4):153-6. PubMed ID: 4052864
    [Abstract] [Full Text] [Related]

  • 27. Iron loading and thalassemia--experimental successes and practical realities.
    Weatherall DJ, Pippard MJ, Callender ST.
    N Engl J Med; 1977 Aug 25; 297(8):445-6. PubMed ID: 560628
    [No Abstract] [Full Text] [Related]

  • 28. Iron excretion in thalassemia children treated with deferoxamin methansulfonat: intravenous drip compared to the subcutaneous routes.
    Hathirat P, Areekul S, Isarangkura P, Chantachum Y.
    J Med Assoc Thai; 1989 Jan 25; 72 Suppl 1():121-4. PubMed ID: 2732632
    [Abstract] [Full Text] [Related]

  • 29. The results of long-term growth hormone replacement therapy in Turkish children with growth hormone deficiency.
    Yordam N, Kandemir N, Alikaşifoğlu A.
    Turk J Pediatr; 1998 Jan 25; 40(1):55-60. PubMed ID: 9673529
    [Abstract] [Full Text] [Related]

  • 30. Pharmacist involvement in a deferoxamine education program for patients with Cooley's anemia.
    Levine HG, Hanan ZI, Gordon FS, Tomasulo WJ.
    Am J Hosp Pharm; 1979 Jun 25; 36(6):788-90. PubMed ID: 463895
    [Abstract] [Full Text] [Related]

  • 31. Intensive iron-chelation in thalassaemia.
    Pignatti CB, De Stefano P.
    Br Med J; 1978 Nov 18; 2(6149):1432-3. PubMed ID: 719440
    [No Abstract] [Full Text] [Related]

  • 32. [Effect of hematologic treatment on the growth and puberty of children with thalassemia major].
    Pomarède R, Girot R, Constant S, Rappaport R.
    Arch Fr Pediatr; 1984 Apr 18; 41(4):255-9. PubMed ID: 6477042
    [Abstract] [Full Text] [Related]

  • 33. Comparison of subcutaneous infusion needles for transfusion-dependent thalassemia patients by the intrapersonal cross-over assessment model.
    Chan GC, Ng DM, Fong DY, Ha SY, Lau YL.
    Am J Hematol; 2004 Aug 18; 76(4):398-404. PubMed ID: 15282678
    [Abstract] [Full Text] [Related]

  • 34. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A, Imbach P, Pfenninger E, Stocker F, Töndury P, Wagner HP, Weber J, Zuppinger K.
    Helv Paediatr Acta; 1985 Sep 18; 40(4):293-304. PubMed ID: 4077563
    [Abstract] [Full Text] [Related]

  • 35. [Growth velocity in thalassemic children receiving different protocols of chelating therapy].
    Elena MG, Fedele A, Gianino P, Giordanino S, Murru P, Tosi C, Vannelli S.
    Minerva Pediatr; 1992 Sep 18; 44(1-2):41-2. PubMed ID: 1552875
    [Abstract] [Full Text] [Related]

  • 36. Subcutaneous desferrioxamine in homozygous beta-thalassaemia.
    Silvestroni E, Bianco I, Graziani B, Carboni C, Costantini S.
    Lancet; 1978 Nov 25; 2(8100):1149-50. PubMed ID: 82705
    [No Abstract] [Full Text] [Related]

  • 37. The simple rubber band technic for slow subcutaneous infusion of desferrioxamine.
    Hathirat P, Sasanakul W, Areekul S, Chantachum Y, Isarangkura P.
    J Med Assoc Thai; 1984 Feb 25; 67(2):89-92. PubMed ID: 6736830
    [No Abstract] [Full Text] [Related]

  • 38. Deferoxamine-induced growth retardation in patients with thalassemia major.
    De Virgiliis S, Congia M, Frau F, Argiolu F, Diana G, Cucca F, Varsi A, Sanna G, Podda G, Fodde M.
    J Pediatr; 1988 Oct 25; 113(4):661-9. PubMed ID: 3171791
    [Abstract] [Full Text] [Related]

  • 39. Continuous subcutaneous administration of deferoxamine in patients with iron overload.
    Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF, Rosenthal A, Nathan DG.
    N Engl J Med; 1977 Aug 25; 297(8):418-23. PubMed ID: 882111
    [Abstract] [Full Text] [Related]

  • 40. Growth and sexual maturation in thalassemia major.
    Borgna-Pignatti C, De Stefano P, Zonta L, Vullo C, De Sanctis V, Melevendi C, Naselli A, Masera G, Terzoli S, Gabutti V.
    J Pediatr; 1985 Jan 25; 106(1):150-5. PubMed ID: 3965675
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.